Genentech: FDA Approves Xofluza to Treat Influenza in Children Aged 5 and Older
August 11 2022 - 4:30PM
Dow Jones News
By Stephen Nakrosis
Genentech on Thursday said the U.S. Food and Drug Administration
approved a supplemental new drug application for its Xofluza to
treat acute uncomplicated influenza in certain patients aged 5 to
12.
The company said Xofluza, or baloxavir marboxil, is the first
single-dose oral influenza medicine approved for children in this
age group.
Genentech said the FDA also approved the treatment for the
prevention of influenza in children in the age group after contact
with someone with influenza.
Xofluza has already been approved by the FDA to treat influenza
in certain patients 12 years of age and older.
Genentech is a member of the Roche Group.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 11, 2022 16:15 ET (20:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
